CA2034489A1 - Methode d'inactivation de virus dans des compositions pharmaceutiques contamines par des virus - Google Patents

Methode d'inactivation de virus dans des compositions pharmaceutiques contamines par des virus

Info

Publication number
CA2034489A1
CA2034489A1 CA2034489A CA2034489A CA2034489A1 CA 2034489 A1 CA2034489 A1 CA 2034489A1 CA 2034489 A CA2034489 A CA 2034489A CA 2034489 A CA2034489 A CA 2034489A CA 2034489 A1 CA2034489 A1 CA 2034489A1
Authority
CA
Canada
Prior art keywords
viruses
inactivation
viral
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2034489A
Other languages
English (en)
Other versions
CA2034489C (fr
Inventor
Michael E. Hrinda
Rose D'alisa
George Crissman Tarr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2034489A1 publication Critical patent/CA2034489A1/fr
Application granted granted Critical
Publication of CA2034489C publication Critical patent/CA2034489C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002034489A 1989-06-15 1990-06-13 Methode d'inactivation de virus dans des compositions pharmaceutiques contamines par des virus Expired - Lifetime CA2034489C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36685589A 1989-06-15 1989-06-15
US366,855 1989-06-15

Publications (2)

Publication Number Publication Date
CA2034489A1 true CA2034489A1 (fr) 1990-12-16
CA2034489C CA2034489C (fr) 1996-07-16

Family

ID=23444851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002034489A Expired - Lifetime CA2034489C (fr) 1989-06-15 1990-06-13 Methode d'inactivation de virus dans des compositions pharmaceutiques contamines par des virus

Country Status (9)

Country Link
US (1) US5300433A (fr)
EP (1) EP0431129B1 (fr)
JP (1) JP3297433B2 (fr)
AT (1) ATE138575T1 (fr)
CA (1) CA2034489C (fr)
DE (1) DE69027187T2 (fr)
DK (1) DK0431129T3 (fr)
ES (1) ES2087156T3 (fr)
WO (1) WO1990015613A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994013329A1 (fr) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Procede de preparation de compositions biologiques exemptes de virus
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
WO1996032130A1 (fr) * 1995-04-10 1996-10-17 Baxter International Inc. Utilisation d'hemoglobine reticulee dans le traitement des hemorragies sous-arachnoidiennes
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7038016B2 (en) * 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
CA2498518A1 (fr) * 2002-09-13 2004-03-25 Valentis, Inc. Appareil et procede de purification a l'echelle de la chimie preparatoire d'acides nucleiques
CA2560613C (fr) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques par voie orale a base de lipases, en particulier de pancreatine, contenant des tensioacitfs
WO2006023774A2 (fr) * 2004-08-20 2006-03-02 Imquest Biosciences, Inc. Fraction de plasma ou de serum pour traiter et prevenir des infections virales et des pathologies liees
KR101555058B1 (ko) * 2005-07-29 2015-09-22 애보트 래버러토리즈 게엠베하 살균된 판크레아틴 분말의 제조방법
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
WO2012069474A2 (fr) * 2010-11-24 2012-05-31 H. Lundbeck A/S Procédé de réduction de la charge virale potentielle dans un échantillon par un traitement au cyanate
CA2821711C (fr) 2010-12-15 2017-10-10 Baxter International Inc. Recuperation d'eluat par utilisation d'un gradient de conductivite
CA2832109C (fr) 2011-06-10 2021-07-06 Oregon Health & Science University Glycoproteines de cmv et vecteurs recombinants cmv
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS61500226A (ja) * 1983-10-28 1986-02-06 ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド コンホメ−ション特異性抗体を用いる血液凝固タンパク質の精製および単離法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) * 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DD264137A1 (de) * 1987-09-22 1989-01-25 Univ Leipzig Mittel zur bekaempfung von viren in kulturpflanzen

Also Published As

Publication number Publication date
ATE138575T1 (de) 1996-06-15
JPH04501429A (ja) 1992-03-12
DK0431129T3 (da) 1996-06-17
WO1990015613A1 (fr) 1990-12-27
EP0431129A1 (fr) 1991-06-12
EP0431129A4 (en) 1992-03-11
EP0431129B1 (fr) 1996-05-29
CA2034489C (fr) 1996-07-16
DE69027187D1 (de) 1996-07-04
ES2087156T3 (es) 1996-07-16
US5300433A (en) 1994-04-05
DE69027187T2 (de) 1996-10-31
JP3297433B2 (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
CA2034489A1 (fr) Methode d&#39;inactivation de virus dans des compositions pharmaceutiques contamines par des virus
US4632980B1 (fr)
AU3310595A (en) Compositions and methods for identifying biologically active molecules
CA2250078A1 (fr) Procedes de replication des virus de la grippe dans une culture cellulaire, et virus de la grippe obtenus selon ce procede
AU578050B2 (en) Desulfatohirudins, the preparation thereof and pharmaceutical compositions containing them
DE69022163D1 (de) Steriles erzeugnis und verfahren zur sterilisierung und zusammenbau dieses erzeugnisses.
BG100293A (en) 2,8-disubstituted quinazolinons
CA2115348A1 (fr) Methode de production de preparations pharmaceutiques injectables ou perfusables contenant des proteines humaines
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DK0404283T3 (da) 11alfa-aryl-4-estrener, fremgangsmåde til fremstilling af disse samt deres anvendelse som lægemidler
EP0233013A3 (fr) Enzyme modifié
EE03353B1 (et) Kristalne 5-atseetamido-2,3,4,5-tetradesoksü-4-guanidino-D-glütsero-D-galaktonon-2-eenpüranosoonh ape, selle valmistamismeetod ja seda sisaldavad farmatseutilised preparaadid
WO1996022305A3 (fr) Peptides modifies
DE3869670D1 (de) Latex fuer die immobilisierung von physiologisch aktiven verbindungen und reaktiver latex, der diesen latex verwendet.
CA2191406A1 (fr) Procede d&#39;extraction de composes aromatiques de solutions contenant un produit
IL95949A0 (en) Process for the preparation of 3-(l-pyroglutamyl)-l-thiazolidine-4-carboxylic acid and its derivatives
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
NO890129D0 (no) Fremgangsmaate ved inaktivering av sykdomsfremkallende materialer i blodplasmaprodukter.
AU568849B2 (en) Inactivation of viruses in virus containing protein samples
ATE96280T1 (de) Verfahren zur herstellung eines pflanzlichen eiweisshydrolysats und so hergestelltes produkt.
CA2096888A1 (fr) Methode d&#39;inactivation des virus dans les preparations contenant des proteines
AU644621B2 (en) Pharmaceutical composition for treating or preventing retroviral infections
DE3762792D1 (de) Schwarztrueffelaroma.
DE68900926D1 (de) Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen.
DE69014501D1 (de) Verfahren zur Behandlung von Titanlegierung und damit hergestelltes Stück.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry